CheckMate914

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

Strengthening Our Grip on Immuno-Oncology in Genitourinary Cancers: Understanding Science Through Stories

EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse

Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

ASCO 2020: A Phase III, Randomized, Placebo-Controlled Trial of Nivolumab or Nivolumab plus Ipilimumab in Patients with Localized Renal Cell Carcinoma at High-Risk of Relapse after Radical or Partial Nephrectomy (CheckMate 914)

Checkpoint inhibitor immunotherapy in kidney cancer

CheckMate-914 trial's disappointing results cast doubt on BMS's plans to advance PD-1 inhibitors

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis - Mori - International Journal of Urology - Wiley Online Library

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

CheckMate914

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials - ScienceDirect

ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial

Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma